COVID-19 Vaccination Recommendations for 2024–2025 in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024–2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations.
Abstract
The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024–2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations.
참고문헌 (37)
- Choi WS, "Revised adult immunization guideline recommended by the korean society of infectious diseases, 2014", Infect Chemother, 47, pp.68~79 (2015)
- Choi WS, "Recommendations for adult immunization by the Korean Society of Infectious Diseases, 2023 : minor revisions to the 3rd edition", Infect Chemother, 56, pp.188~203 (2024)
- Kang JH, "Adult immunization schedule recommended by the Korean Society of Infectious Diseases, 2007", Infect Chemother, 40, pp.1~13 (2008)
- Park WB, "COVID-19 vaccination in Korea", Infect Chemother, 55, pp.135~149 (2023)
- Kang SJ, "Age-related aorbidity and aortality among patients with COVID-19", Infect Chemother, 52, pp.154~164 (2020)
- Kim M, "Clinical characteristics and risk factors for severe disease of coronavirus disease 2019 in a low case fatality rate region in Korea", Infect Chemother, 53, pp.718~729 (2021)
- "WHO COVID-19 dashboard: number of COVID-19 cases reported to WHO"[URL]
- "WHO COVID-19 dashboard: COVID-19 vaccination, world data"[URL]
- Abu-Raddad LJ, "Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar", N Engl J Med, 386, pp.1091~1093 (2022)
- Thomas SJ, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months", N Engl J Med, 385, pp.1761~1773 (2021)
- "Use of COVID-19 vaccines in the United States – interim clinical considerations"[URL]
- "Statement on the antigen composition of COVID-19 vaccines, 2024 Apr 26"[URL]
- "COVID data tracker - variant proportions"[URL]
- "Current status of COVID-19 genetic analysis"[URL]
- Panagiotakopoulos L, "Use of COVID-19 vaccines for persons aged ≥6 months : recommendations of the advisory dommittee on immunization practices-United States, 2024-2025", MMWR Morb Mortal Wkly Rep, 73, pp.819~824 (2024)
- Kaku Y, "Virological characteristics of the SARS-CoV-2 JN. 1 variant", Lancet Infect Dis, 24, pp.e82~ (2024)
- Kaku Y, "Virological characteristics of the SARS-CoV-2 KP. 2 variant", Lancet Infect Dis, 24, pp.e416~ (2024)
- Kaku Y, "Virological characteristics of the SARS-CoV-2 KP. 3, LB. 1, and KP. 2. 3 variants", Lancet Infect Dis, 24, pp.e482~e483 (2024)
- "COVID-19 vaccines: Canadian immunization guide"[URL]
- "EMA confirms its recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024-2025"[URL]
- Andersson NW, "Comparative effectiveness of bivalent BA. 4-5 and BA. 1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries : nationwide cohort study", BMJ, 382, pp.e075286~ (2023)
- "COVID-19 vaccination programme - information for healthcare practitioners, version 7.0"[URL]
- Ramsay M, "Immunisation against infectious disease", pp.1~55 (2020), UK Health Security Agency
- "COVID-19 vaccine and therapeutic product approval and review"[URL]
- Li P, "Neutralization escape, infectivity, and membrane fusion of JN. 1-derived SARS-CoV-2 SLip, FLiRT, and KP. 2 variants", Cell Rep, 43, pp.114520~ (2024)
- Seo JW, "Updated clinical practice guidelines for the diagnosis and management of long COVID", Infect Chemother, 56, pp.122~157 (2024)
- Bergeri I, "Global SARS-CoV-2 seroprevalence from January 2020 to April 2022 : a systematic review and meta-analysis of standardized population-based studies", PLoS Med, 19, pp.e1004107~ (2022)
- Han J, "Korea seroprevalence study of monitoring of SARS-COV-2 antibody retention and transmission(K-SEROSMART) : findings from national representative sample", Epidemiol Health, 45, pp.e2023075~ (2023)
- Menegale F, "Evaluation of waning of SARS-CoV-2 vaccine-induced immunity : a systematic review and meta-analysis", JAMA Netw Open, 6, pp.e2310650~ (2023)
- Park JS, "Magnitude and duration of serum neutralizing antibody titers induced by a third mRNA COVID-19 vaccination against omicron BA. 1 in older individuals", Infect Chemother, 56, pp.25~36 (2024)
- Buchan SA, "Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada", JAMA Netw Open, 5, pp.e2218505~ (2022)
- "Effectiveness of COVID-19 vaccines. Presented to the ACIP October 2024"[URL]
- "COVID-19–associated hospitalizations update — COVID-NET, July 2023–September 2024. Presented to the ACIP October 2024"[URL]
- "Economic analysis of an additional dose of the 2024-2025 COVID-19 vaccine"[URL]
- "COVID-19 autumn 2023 booster programme: cost effectiveness impact assessment"[URL]
- "JCVI statement on COVID-19 vaccination in 2025 and spring 2026"[URL]
- "Underlying conditions and the higher risk for severe COVID-19"[URL]